Intervention not reported
Number of subjects who had one or more exacerbations over the study period in children and adolescents ( · Adults and children with asthma
The intervention showed no clear difference in number of subjects who had one or more exacerbations over the study… (moderate certainty).
1 finding from 1 review
Intervention not reported
Contrast threshold loss ‐0.15 log units or more at 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration
The intervention showed no clear difference in contrast threshold loss ‐0.15 log units or more at 1 year (moderate certainty).
1 finding from 1 review
Intervention not reported
Reading speed 40 word/minute or more after 1 year · patients with choroidal neovascularisation secondary to age‐related macular degeneration
The intervention showed no clear difference in reading speed 40 word/minute or more after 1 year (high certainty).
1 finding from 1 review
Radiographic progression · patients with rheumatoid arthritis
1 finding from 1 review
BCVA: loss of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Six or more lines visual acuity lost · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to lower loss of 6 or more lines (30 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to higher gain of 3 or more lines (15 or more letters) compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 300/450 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 400/450 IU vs 300 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in IU vs 450 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
It is very uncertain whether attention deficit hyperactivity disorder (ADHD)‐related drugs changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Antidepressants may leads to higher adverse effects compared with placebo (low certainty).
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Adverse effects (AEs) · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Atypical antipsychotics may leads to higher adverse effects (AEs) compared with placebo (low certainty).
1 finding from 1 review